D.J. St. Germain’s 10x Genomics TXG Stock Holding History

D.J. St. Germain’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.99K	Hold	52	–	–	﹤0.01%	825
2026 Q1	$1.1K	Hold	52	–	–	﹤0.01%	844
2025 Q4	$848	Hold	52	–	–	﹤0.01%	853
2025 Q3	$608	Hold	52	–	–	﹤0.01%	855
2025 Q2	$602	Hold	52	–	–	﹤0.01%	831
2025 Q1	$454	Hold	52	–	–	﹤0.01%	770
2024 Q4	$747	Hold	52	–	–	﹤0.01%	779
2024 Q3	$1.17K	Buy	+52	New	+$1.07K	﹤0.01%	702

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

D.J. St. Germain's TXG Position: Q2 2026 in Review

D.J. St. Germain held its 10x Genomics (TXG) position steady in Q2 2026 at 52 shares worth $1.99K. The position accounts for ﹤0.01% of the portfolio, ranked #825.

D.J. St. Germain first reported a position in TXG in Q3 2024 and has held it in 8 quarters since. 392 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

D.J. St. Germain held 52 shares of 10x Genomics worth $1.99K as of Q2 2026.
D.J. St. Germain left its 10x Genomics share count unchanged in Q2 2026.
10x Genomics made up ﹤0.01% of D.J. St. Germain's portfolio in Q2 2026, its #825 holding.
D.J. St. Germain first reported a position in 10x Genomics in Q3 2024 and has held it in 8 quarters since.
392 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on D.J. St. Germain's 13F filing for Q2 2026, filed 21 Jul 2026.